A Phase II Study of Boron Neutron Capture Therapy (BNCT) for Patients With Unresectable Angiosarcoma, by Using CICS-1 and SPM-011
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Borofalan (10B) (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- Sponsors Stella Pharma
Most Recent Events
- 09 Apr 2025 Planned End Date changed from 30 Apr 2025 to 31 Aug 2025.
- 19 Sep 2024 Planned primary completion date changed from 31 Jul 2024 to 30 Nov 2024.
- 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.